The long-awaited Free-Trade Agreement between the USA and South Korea, which had been stalled to a large extent because of the interests of the pharmaceutical industry, has at last been concluded, making it the latest under the US presidential Trade-Promotion Authority (Marketletters passim), the Office of the US Trade Representative announced earlier this month.
The agreement was concluded April 1, the last day the TPA allows the president to submit free-trade agreements to Congress for an up or down vote, without amendments. Congress has 90 days to consider the deal before TPA expires on June 30.
With the pending expiration of the TPA, also called fast-track authority, the USA does not plan to start any new FTA negotiations, said Sean McCormack, state department spokesman. Fast-track authority was granted to President George W Bush in 2001, when the House of Representatives was controlled by Republicans. With Democrats now in control in Congress, renewal of the TPA is uncertain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze